About Integral membrane protein GPR137
Integral membrane protein GPR137 (GPR137) is a protein
from Homo sapiens identified by UniProt accession
Q96N19, 417 residues long.
MolForge cross-references it against 0 known binders and
71 disease associations.
Target properties
| Protein name | Integral membrane protein GPR137 |
| UniProt accession | Q96N19 |
| Gene | GPR137 |
| Organism | Homo sapiens |
| Length | 417 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (71)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.53
- heel bone mineral density · score 0.17
- platelet count · score 0.13
- urate measurement · score 0.09
- attention deficit hyperactivity disorder · score 0.09
- red blood cell density measurement · score 0.08
- urinary bladder carcinoma · score 0.07
- schizophrenia 15 · score 0.07
- attention deficit-hyperactivity disorder 8 · score 0.07
- body mass index · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96N19-F1 | alphafold | PREDICTED | 66.17 | — |
Amino-acid sequence (417 residues)
MESNLSGLVP AAGLVPALPP AVTLGLTAAY TTLYALLFFS VYAQLWLVLL YGHKRLSYQT VFLALCLLWA ALRTTLFSFY FRDTPRANRL GPLPFWLLYC CPVCLQFFTL TLMNLYFAQV VFKAKVKRRP EMSRGLLAVR GAFVGASLLF LLVNVLCAVL SHRRRAQPWA LLLVRVLVSD SLFVICALSL AACLCLVARR APSTSIYLEA KGTSVCQAAA MGGAMVLLYA SRACYNLTAL ALAPQSRLDT FDYDWYNVSD QADLVNDLGN KGYLVFGLIL FVWELLPTTL LVGFFRVHRP PQDLSTSHIL NGQVFASRSY FFDRAGHCED EGCSWEHSRG ESTRCQDQAA TTTVSTPPHR RDPPPSPTEY PGPSPPHPRP LCQVCLPLLA QDPGGRGYPL LWPAPCCSCH SELVPSP
Explore Integral membrane protein GPR137 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets